Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 33 of 33

Filter Applied: myasthenia gravis (Click to remove)

Transient Myasthenia Gravis During HIV Infection
Muscle & Nerve 18:914-916995., Authier,F-J.,et al, 1995

The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathology 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001

Primary CNS Lymphoma in Myasthenic on Long-term Azathioprine
J NeuroOncol 74:91-92, Finelli,P.F., 2005

Primary CNS Lymphoma Complicating Treatment of Myasthenia Gravis with Mycophenolate Mofetil
Neurol 65:639-641, Vernino,S.,et al, 2005

The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathol 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001

Association of Primary Central Nervous System Lymphoma with Long-Term Azathioprine Therapy for Myasthenia Gravis?
Ann Neurol 47: 682-683, Herrlinger,U.,et al, 2000

Progressive Multifocal Leukoencephalopathy in Myasthenia Gravis
Ann Neurol 11:218-219, Dawson,D.M., 1982

Familial Neuromuscular Disease with Type 1 Fiber Hypoplasia, Tubular Aggregates, Cardiomyopathy, & Myasthenic Features
Neurol 28:1135-1140, Dobkin,B.H.,et al, 1978

Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018

Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018

Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016

Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016

Overlooked non-motor Symptoms in Myasthenia Gravis
JNNP 84:989-994, Suzuki, S.,et al, 2013

Concomitant Chronic Inflammatory Demyelinating Polyneuropathy and Myasthenia Gravis Following Cytomegalovirus Infection
J Neurol Sci 240:103-106, Mori, M.,et al, 2006

Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999

Myasthenic Crisis:Clinical Features, Mortality, Comp, & Risk Factors for Prolonged Intubation
Neurol 48:1253-1254, Thomas,C.E.,et al, 1997

Myasthenia Gravis and Sarcoidosis:Report of 2 Cases
Eur Neurol 36:326-327, DeBleecker,J.,et al, 1996

Differential Diagnosis of Guillain-Barre Synd, In Guillain-Barre Synd
Thieme Med Publ, Ch 3, p 42993., Parry,G.J., 1993

Recurrent Transverse Myelitis, Myasthenia Gravis, and Autoantibodies
Ann Neurol 32:407-409, Lindsey,J.W.,et al, 1992

Genetic Factors in Myasthenia Gravis:A Family Study
Neurol 38:38-42, Kerzin-Storrar,L.,et al, 1988

Facioscapulohumeral Muscular Dystrophy, in Neuromuscular Disease
Springer-Verlag, NY, p289988., Swash,M.&Schwartz,M.S., 1988

Circulating Immune Complexes in Neurologic Disease
Neurol 31:1402-1407, Noronha,A.B.C.,et al, 1981

HLA & Neurologic Fisease
Neurol 28:413, Compston,A., 1978

Serum Antibodies to Cytomegalovirus in Myasthenia Gravis:Effects of Thymectomy & Steroids
Neurol 28:273, Tindall,R.S.A.,et al, 1978

Cause of Weakness in Myasthenia Gravis
NEJM 294:722, Grob,D., 1976

Epidemiology of Motor-Neuron Diseases
NEJM 288:1047, Bobwick,A.R.,et al, 1973

Neurologic Manifestations of SLE 1972
Nebraska State Journ Med, Oct 1972, pp 395., Aita,J., 1972

Diseases of Muscles-Clinical Manifestations & Differential Diagnosis
The New Physic 263, 1967, Oct., Boshes,L., 1967

Neuro CPC of MGH
Myopathy, Severe, Generalized, Chronic, NEJM 258:388-3938., , 1958



Showing articles 0 to 33 of 33